1 / 3

Hepatic Biomarkers Market Size & Growth

Browse 159 Market Data Tables and 119 Figures spread through 189 Pages and in-depth TOC on "Global Non-invasive Prenatal Testing Market - Forecast to 2026" <br>https://www.globalmarketestimates.com/market-report/global-non-invasive-prenatal-testing-market-3045<br>

Globalestimates
Download Presentation

Hepatic Biomarkers Market Size & Growth

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Hepatic Biomarkers Market Size & Analysis - Forecast to 2026 The findings reviewed by GME stated that the Global Hepatic Biomarkers Market will grow at a CAGR value of 6.5% from 2021 to 2026.The increasing prevalence of chronic diseases, like cancers and other chronic diseases, is raising the use of hepatic biomarkers all over the world. Browse 159 Market Data Tables and 119 Figures spread through 189 Pages and in-depth TOC on "Global Hepatic Biomarkers Market - Forecast to 2026" https://www.globalmarketestimates.com/market-report/global-hepatic-biomarkers-market-3046 By Type (Serum Biomarkers, Hepatic Fibrosis Biomarkers, Apoptosis Biomarkers, Oxidative Stress Biomarkers, Other Biomarkers), By End-User (Pharma & CRO Industry, Hospitals, Diagnostic Labs, Academic Research Institutes), By Region (North America, Asia Pacific, Europe, Latin America, Middle East & Africa), End-User Landscape, Company Market Share Analysis, and Competitor Analysis Key Market Insights •The rising demand for non-intrusive symptomatic diagnostic devices is estimated to fuel the demand for hepatic biomarkers. •The demand for the academic research institutes segment will expand at a faster rate owing to ongoing research and development projects to develop COVID-19 vaccines. •The market segment of serum biomarkers will possess a larger share because of its ability to distinguish streamlined steatosis from hepatic biomarkers and accurate results rates. •North America will be the market leader owing to the surge in investments for producing advanced hepatic biomarkers. •Eli Lilly & Co., Bruker Daltonics, Inc, LLC., Agilent Technologies; EUSA Pharma Biomarker Technologies, Abbott, CytoCore Inc., BioCurex, and GE Healthcare, Inc. are some of the most significant players in this market. Browse the Report @ https://www.globalmarketestimates.com/market-report/global-hepatic-biomarkers- market-3046 Type Outlook (Revenue, USD Billion, 2021-2026) •Serum Biomarkers •Hepatic Fibrosis Biomarkers

  2. •Apoptosis Biomarkers •Oxidative Stress Biomarkers •Other Biomarkers End-User Outlook (Revenue, USD Billion, 2021-2026) •Pharma & CRO Industry •Hospitals •Diagnostic Labs •Academic Research Institutes Regional Outlook (Revenue, USD Billion, 2021-2026) North America •The U.S. •Canada •Mexico Europe •Germany •UK •France •Spain •Italy •Rest of Europe Asia Pacific •China •India •Japan •South Korea •Australia •Rest of APAC

  3. Central & South America •Brazil •Argentina •Rest of CSA Middle East & Africa •Saudi Arabia •UAE •Rest of MEA Contact: Tracy Simon Email address: tracy.simon@globalmarketestimates.com Phone Number: +16026667238 Website: https://www.globalmarketestimates.com/ Check our Latest Blogs: https://www.globalmarketestimates.com/blog-posts.php

More Related